Kushim Tablets (Gushim) 45-count packages, Label in foreign language
Published February 19, 2020 · Recall initiated: January 28, 2020
Summary
FDA records drug Class II recall D-0840-2020, published February 19, 2020 and initiated January 28, 2020. Recalling firm: B AND A TRADING CORPORATION; Status: Terminated; Reported quantity: 40 packages; Lot: Lot #: H003. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Marketed Without an Approved NDA/ANDA. FDA analysis found product to contain cinobufagin, bufalin, and bufotenine
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- B AND A TRADING CORPORATION
- Distributor
- NY & NJ only
- Lot
- Lot #: H003
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAHydrocortisone and Acetic Acid Otic Solution, USP, 10 mL dropper bottle, Rx only, HI-TECH PHARMACAL CO., INC.,February 19, 2020
- FDACaduet (amlodipine besylate/atorvastatin calcium) Tablets, 10 mg/20 mg*, 30-count bottle, Rx only, DistributedFebruary 19, 2020
- FDAMethylphenidate hydrochloride Extended-Release ablets USP (CII), 27 mg, 100-count bottle, Rx only, TevaFebruary 19, 2020
- FDACaduet (amlodipine besylate/atorvastatin calcium) Tablets, 10 mg/10 mg*, 30-count bottle, Rx only, DistributedFebruary 19, 2020
- FDAMethylphenidate hydrochloride Extended-Release ablets USP (CII), 18 mg, 100-count bottle, Rx only, TevaFebruary 19, 2020
- FDAFrovatriptan Succinate Tablets, 2.5mg, packaged in 1 blister card of 9 tablets per carton, Rx Only,February 19, 2020
Questions about this recall
Was Kushim Tablets (Gushim) 45-count packages, Label in foreign language recalled?
Yes. FDA published recall D-0840-2020 on February 19, 2020. Reported hazard: Marketed Without an Approved NDA/ANDA. FDA analysis found product to contain cinobufagin, bufalin, and bufotenine
What should I do if I have this product?
Voluntary: Firm initiated · Letter